Translational research in wasting diseases: Edited by Vickie E. Baracos, Didier Attaix and Claude PichardTwo faces of drug therapy in cancer: drug-related lean tissue loss and its adverse consequences to survival and toxicityPrado, Carla MMa; Antoun, Samib; Sawyer, Michael Ba; Baracos, Vickie EaAuthor Information aDepartment of Oncology, Cross Cancer Institute, University of Alberta, Edmonton, Alberta, Canada bDepartment of Supportive Care, Institut Gustave Roussy, Villejuif, France Correspondence to Vickie E. Baracos, Department of Oncology, Cross Cancer Institute, University of Alberta, 11560 University Avenue, Edmonton, AB T6G 1Z2, Canada E-mail: [email protected] Current Opinion in Clinical Nutrition and Metabolic Care: May 2011 - Volume 14 - Issue 3 - p 250-254 doi: 10.1097/MCO.0b013e3283455d45 Buy Metrics Abstract Purpose of review A common feature of cancer patients is loss of lean tissue, specifically skeletal muscle, which may be the result of the tumor or a side-effect of chemotherapy or other drugs. Lean tissue loss in turn has important adverse implications for toxicity of antineoplastic therapy and, hence, cancer prognosis. Recent findings Contemporary cancer populations have heterogeneous proportions of lean tissue, regardless of body weight. Wasting of lean tissue during the cancer trajectory has been associated with tumor progression. Lean tissue depletion is an independent predictor of severe toxicity in patients treated with chemotherapeutic agents of diverse classes. Patients with lean tissue depletion behave as if overdosed and have toxicity of sufficient magnitude to require dose reductions, treatment delays or definitive termination of treatment. Muscle loss may occur due to a specific effect of a chemotherapy agent (i.e. sorafenib), androgen suppression therapy or other drugs (i.e. statins such as atorvastatin). Summary Lean tissue wasting occurs due to cancer progression and may be exacerbated by several drug classes. This loss of lean tissue is not proportional to changes in body weight and is prognostic of enhanced treatment toxicity and reduced survival. © 2011 Lippincott Williams & Wilkins, Inc.